newsfilter
← Latest News
GlobeNewswire·

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...